RxDoctor Payments Data

Preston Edge, MD

Urogynecology and Reconstructive Pelvic Surgery · Newburgh, INNPI 1023544475

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $3,556 of the $5,227 with a category attached, or 68.0%. 12 manufacturers reported payments, led by Axonics, Inc. at 43.5% of the total. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in IN, where the typical reported total is $5,227.

$5,227in general payments, 2019–2025

Across 46 payments — averaging $113.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Boston Scientific$2K
  • Medical Device Business Services, Inc.$325
  • Caldera Medical, Inc$241
  • Sumitomo Pharma America, Inc.$161
  • Medtronic$110
  • plus $202 from 6 others

What the payments were for

  • Travel & lodging$3,55668%
  • Food & beverage$1,34626%
  • Education$3256%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,227 in reported general payments places this provider in the 50th percentile of 21 urogynecology and reconstructive pelvic surgery providers in Indiana.

See all urogynecology and reconstructive pelvic surgery providers in Indiana

Medicare billing

Part B allowed, 2024
$28,431
Medicare patients
49
Services billed
448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron16$12,385
GemtesaVibegron16$7,726
Estradiol36$2,324
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$101
Ibuprofen13$40
Oxycodone Hcl13$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$161$7,72616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 21 urogynecology and reconstructive pelvic surgery providers in Indiana.

Other urogynecology and reconstructive pelvic surgery in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →